scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1022283631 |
P356 | DOI | 10.1007/BF01061419 |
P698 | PubMed publication ID | 2834209 |
P2093 | author name string | G G Geyskes | |
B A van Schaik | |||
H H van Rooij | |||
A J Porsius | |||
P A van der Wouw | |||
P2860 | cites work | Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521 | Q41875348 |
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects | Q42098372 | ||
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system | Q42117586 | ||
Enalapril maleate and a lysine analogue (MK-521): disposition in man | Q42264743 | ||
Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. | Q42532122 | ||
Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. | Q51634342 | ||
Lisinopril in hypertensive patients with and without renal failure. | Q54141536 | ||
Drug dosage in patients with renal disease. | Q54235166 | ||
Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitor | Q70182769 | ||
P433 | issue | 1 | |
P921 | main subject | pharmacokinetics | Q323936 |
P304 | page(s) | 61-65 | |
P577 | publication date | 1988-01-01 | |
P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
P1476 | title | Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function | |
P478 | volume | 34 |
Q40891443 | Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure |
Q37950596 | Clinical pharmacokinetics of the newer ACE inhibitors. A review |
Q47913024 | Clinical pharmacokinetics of vasodilators. Part I. |
Q44917912 | Comparison of the Steady-State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Patients with Chronic Renal Insufficiency |
Q36055004 | Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency |
Q38378935 | Effects of cardiovascular disease on pharmacokinetics |
Q72894682 | Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment |
Q37268536 | Pharmacokinetics of newer drugs in patients with renal impairment (Part II). |
Q35952552 | Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection |
Q98163692 | Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model |
Q90774040 | Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration |
Q28333134 | The pharmacokinetics of benazepril relative to other ACE inhibitors |
Search more.